with eyes set on the future

Investment
Innovation
Internationalization
Quality
Partnership

bluepharma 20 years
Who we are

Bluepharma is a privately owned portuguese pharmaceutical group.

Through the entrepreneurship of its promoters, Bluepharma Group currently comprises 20 innovative companies that cover all stages of the pharmaceutical industry value chain.

Bluepharma’s R&D-based strategy allowed to target the most demanding markets.

Bluepharma offers an integrated approach, including innovative research as well as the development, manufacturing and commercialization of medicines. This has proven to be determinant in our differentiation and competitiveness.

State of the art equipment and highly qualified team.
## Our integrated approach

Bluepharma offers an integrated approach, providing support on all steps of the product development, from R&D to market.

## Why work with us

<table>
<thead>
<tr>
<th>Feature</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leading contract developer and manufacturer</td>
<td>with an integrated approach.</td>
</tr>
<tr>
<td>Full-scale development projects</td>
<td>with a proven track-record in international product launches.</td>
</tr>
<tr>
<td>Right First Time</td>
<td>Long-term partnerships, based on time to market, cost-awareness and a result-driven strategy.</td>
</tr>
<tr>
<td>On Time in Full</td>
<td>R&amp;D Centers and Manufacturing plants in Portugal.</td>
</tr>
<tr>
<td>Lean Six Sigma</td>
<td>Capability to develop and manufacture high potency products.</td>
</tr>
<tr>
<td>Reduced Lead Time</td>
<td>EU-GMP approved unit, successfully inspected 5 times by US FDA (2009, 2012, 2014, 2016, 2019) and also by MFDS (Republic of Korea), MOH Libya, SFDA (Kingdom of Saudi Arabia), ANVISA (Brazil) and Minpromtorg (Russian Federation). Additionally, the manufacturing site is registered in Iraq, Jordan, Kurdistan, Taiwan, UAE and Vietnam.</td>
</tr>
</tbody>
</table>
Policies
Investment
Innovation
Internationalization
Partnerships
Quality

Where we are

Bluepharma collaborates globally with major pharmaceutical companies through licensing of its own technology or distribution of its own brand.
Innovative Solutions

**Oral Thin Films**
- BlueOS®

Development of novel and versatile Oromucosal delivery formulations, aiming to provide solutions to unmet medical needs through Value Added Medicines.

**Buccal Sprays**
- BluEase™

**Complex Injectables**
- BlueCl™

Development of Complex Injectable formulations, that offer unique advantages and solve major challenges of conventional oral or parenteral drug delivery systems.

Development of advanced formulations that aim the modulation of the release profile, overcome barriers such as incompatibilities between molecules and increase of the stability, including multi-layer tablets, micro tablets, capsule-in-capsule and Hot Melt Extrusion technologies.

---

**Luzitin**

Research and development of novel therapeutic strategies for cancer. The lead compound, Redaporfin, has been granted Orphan Drug Designation (ODD) from both EMA and FDA and achieved successful results from its phase I–IIa clinical trial in advanced head and neck cancer.

---

**TREAT-U**

Research and development of innovative targeted nanoparticles (PEGASEMP®) capable of targeting two distinct cell populations in the tumor: the cancer cells and the blood vessels that nurture the tumor. Orphan Drug Designation (ODD) has been granted to PEGASEMP® from both EMA and FDA. PEGASEMP® has completed a formal non-clinical program and preparation of entry-into-humans study is undergoing.

---

**+25%**

R&D INVESTMENT OVER TURNOVER
Our Value

Bluepharma’s aim is to **create value through innovation**.

This is achieved in dedicated R&D facilities that offer services ranging from the formulation and analytical development to the design of novel delivery platforms, as well as dedicated facilities for high potency drugs.
INTEGRATED APPROACH
FULL RANGE OF SERVICES
TIME TO MARKET
COMPETITIVE PRICES
HIGH STANDARDS OF QUALITY
INTERNATIONAL TRACK RECORD
EXPERTIZE IN CONTRACT DEVELOPMENT
EXTENSIVE AND DIFFERENTIATED PORTFOLIO

Bluepharma’s facilities are EU-GMP certified and approved by MFDS (Republic of Korea), ANVISA (Brazil), MOH Libya, SFDA (Kingdom of Saudi Arabia), Minpromtorg (Russian Federation) and by US FDA (2009, 2012, 2014, 2016, 2019).
We are registered in Iraq, Jordan, Kurdistan, Taiwan, UAE and Vietnam.